"Scientists are reporting early but promising results from a new drug that blocks HIV as it attempts to invade human cells," HealthDay News/U.S. News & World Report. "The approach differs from most current antiretroviral therapy, which tries to limit the virus only after it has gained entry to cells," the news service adds (Gardner, 12/22). "The drug, being developed by small privately held Hannover-based firm VIRO Pharmaceuticals, is called VIR-576 and reduced the amount of HIV infection in the blood by as much 95 percent in an early-stage trial of 18 patients," Reuters reports (Kelland, 12/23). "At the same time, adverse effects were few and mainly involved injection site reactions, [researchers] reported online in Science Translational Medicine," MedPage Today reports (Smith, 12/22).
Back to other news for December 2010
This information was reprinted from kff.org with permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives, and sign up for email delivery. © Henry J. Kaiser Family Foundation. All rights reserved.
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy